European Heart Journal

Journal

Publication Venue For

  • Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering:ODYSSEY OUTCOMES trial.  41:4245-4255. 2020
  • Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: Prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.  41:4114-4123. 2020
  • Salt and cardiovascular disease: Insufficient evidence to recommend low sodium intake.  41:3363-3373. 2020
  • Hypertensive coronary microvascular dysfunction: A subclinical marker of end organ damage and heart failure.  41:2366-2375. 2020
  • Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: An ODYSSEY OUTCOMES trial analysis.  41:2248-2258. 2020
  • Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: A propensity-matched analysis of Medicare claims data.  40:3046-3054. 2019
  • Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial.  40:2801-2809. 2019
  • Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints.  40:880-886. 2019
  • Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification.  40:441-451. 2019
  • Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study.  39:3641-3653. 2018
  • Take a blood pressure pill or benefit from renal denervation?.  39:3010-3012. 2018
  • Final Farewell to Alberto Zanchetti MD..  39:2616-2617. 2018
  • Acellular therapeutic approach for heart failure: In vitro production of extracellular vesicles from human cardiovascular progenitors.  39:1835-1847. 2018
  • Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials.  39:1687-1697. 2018
  • International recommendations for electrocardiographic interpretation in athletes.  39:1466-1480. 2018
  • Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.  39:840-849. 2018
  • Christiaan Barnard's defining moment: The epic first human heart transplant performed 50 years ago by Chris Barnard is discussed by David Cooper MD who was with Barnard at Groote Schuur Hospital in Cape Town.  38:3400-3401. 2017
  • The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: Update 2016.  38:2930-2935. 2017
  • Global position paper on cardiovascular regenerative medicine.  38:2532-2546. 2017
  • The technical report on sodiumintake and cardiovascular disease in low- and middleincome countries by the joint working group of theWorld Heart Federation, the European Society of Hypertension and the European Public Health Association.  38:712-719. 2017
  • Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes andmultivessel coronary artery disease with or without chronic kidney disease.  37:3440-3447. 2016
  • Valvular heart disease in older adults: Seeking an ounce of prevention.  37:3523-3524. 2016
  • Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study.  37:2544-2551. 2016
  • The TACTICS initiative: Time for a Global Alliance on Cardiovascular Regenerative Medicine.  37:2208-2211. 2016
  • CardioPulse. The SPRINT trial results.  37:924-927. 2016
  • The SPRINT trial results.  37:925-927. 2016
  • Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.  37:466-472. 2016
  • Mechanical Dyssynchrony: A Risk Factor but not a Target.  37:60-62. 2016
  • Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: First clinical case report.  36:2011-2017. 2015
  • Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: A translational experience.  36:743-750. 2015
  • Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.  36:219-227. 2015
  • Alcohol consumption and risk of heart failure: The Atherosclerosis Risk in Communities Study.  36:939-945. 2015
  • Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.  36:623-631. 2015
  • Function over form? Assessing the left atrium in heart failure.  36:711-714. 2015
  • A rare coronary anomaly: Origin of the right coronary artery from the left ventricular outflow tract.  35:2811. 2014
  • Combined intracardiac and epicardial device closure of a large left ventricular pseudoaneurysm.  35:2031. 2014
  • Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.  35:1457-1465. 2014
  • Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.  35:3442-3451. 2014
  • Heart failure with preserved ejection fraction: A forest of a variety of trees.  35:3410-3412. 2014
  • Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.  35:42-47. 2014
  • Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.  35:932-941. 2014
  • Digoxin for patients with atrial fibrillation and heart failure: Paradise lost or not?.  34:1468-1470. 2013
  • Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: Findings from post hoc propensity-matched analysis of the AFFIRM trial.  34:1489-1497. 2013
  • Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency.  34:676-683. 2013
  • Third universal definition of myocardial infarction.  33:2551-2567. 2012
  • Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction..  33:1716-1717. 2012
  • Cardioprotective effect of calcineurin inhibition in an animal model of renal disease.  32:1935-1945. 2011
  • Physiological concentration of glutamine increases exogenous fatty acid utilization in the ex vivo working heart: role of the hexosamine biosynthetic pathway.  32:1003-1003. 2011
  • Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: The MADIT-CRT trial.  32:1720-1729. 2011
  • Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.  32:1227-1234. 2011
  • Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: Potential mechanistic insights from epidemiological data.  32:712-720. 2011
  • Boomerang-shaped heart in isolated dextroversion.  32:247. 2011
  • Hip fractures and heart failure: Findings from the Cardiovascular Health Study.  31:77-84. 2010
  • A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: A propensity-matched study.  30:2029-2037. 2009
  • Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: A population-based prospective study of middle-aged and elderly men.  30:1495-1500. 2009
  • Dipyridamole promotes ischemia-induced angiogenesis and tissue blood flow in critical limb ischemia througha PKA dependent nitric oxide pathway.  29:241-241. 2008
  • A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure.  28:1334-1343. 2007
  • Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.  28:1440-1447. 2007
  • Digoxin and reduction in mortality in systolic and diastolic heart failure at low serum digoxin concentrations [5].  27:1630. 2006
  • Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methods.  27:1431-1439. 2006
  • Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study.  27:1408-1415. 2006
  • The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart.  27:1338-1340. 2006
  • Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial.  27:178-186. 2006
  • Skeletal myoblast transplantation through a catheter-based coronary sinus approach: An effective means of improving function of infarcted myocardium.  26:1551-1556. 2005
  • Hormone treatment - Misconceptions and agreements [4] (multiple letters).  23:89-91. 2002
  • Hormone treatment--misconceptions and agreements..  23:89-91. 2002
  • Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.  21:2005-2013. 2000
  • Simultaneous imaging of transmembrane potential and intracellular calcium in myocyte cultures.  21:549-549. 2000
  • Abciximab therapy in percutaneous intervention: economic issues in the United States..  19 Suppl D:D52-D58. 1998
  • Increased platelet activation and fibrinogen in Asian Indians. Potential implications for coronary risk.  19:720-726. 1998
  • Uniformity of captopril benefit in the SAVE study: Subgroup analysis.  15:2-8. 1994
  • Triiodothyronine therapy in open-heart surgery: From hope to disappointment.  14:629-633. 1993
  • Clinical use of automatic implantable defibrillators..  8 Suppl D:143-147. 1987
  • Clinical use of automatic implantable defibrillators.  8:143-147. 1987
  • Protective effects of cardioplegia on diastolic function of hypertrophied rat hearts after hypothermic ischaemic arrest..  5 Suppl F:347-353. 1984
  • Protective effects of cardioplegia on diastolic function of hypertrophied rat hearts after hypothermic ischaemic arrest.  5:347-353. 1984
  • International Standard Serial Number (issn)

  • 0195-668X
  • Electronic International Standard Serial Number (eissn)

  • 1522-9645